ArticlePloS one2020
Anti-biofilm activity of chlorhexidine digluconate against Candida albicans vaginal isolates.
Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 33 citations in OpenAlex.
- Vaginal chlorhexidine gluconate versus fluconazole for recurrent vulvovaginal candidiasis: A randomized noninferiority trial.PloS one · 2026Trial
- Chemical Composition, Antimicrobial, Antibiofilm Activities, and Cytotoxicity of the Essential Oil ofPlants (Basel, Switzerland) · 2026Article
- Targeting Oral Biofilms: Comparative In Vitro Evaluation of Commercial Dental Antiseptics Against Clinical and Reference Microbial Strains.International journal of molecular sciences · 2026Article
- Pseudolaric Acid B Combats Drug-Resistant Candida albicans Infection via Dual-Action Mechanisms of Direct Antifungals and Vaginal Microbiota Restoration.Microbial biotechnology · 2026Article
- Advances in vulvovaginal candidiasis research: a comprehensive review from epidemiology, diagnosis, treatment to resistance mechanisms.Frontiers in microbiology · 2026Review
- Chemical-Assisted Microwave Disinfection Used to EradicateJournal of functional biomaterials · 2025Article
- The role of biogenic aluminium oxide nanoparticles (AlScientific reports · 2025Article
- What is the most advantageous lavage solution to use for fungal prosthetic joint infections.Journal of clinical orthopaedics and trauma · 2025Article
- Repurposing Mouthwashes: Antifungal and Antibiofilm Abilities of Commercially Available Mouthwashes AgainstAntibiotics (Basel, Switzerland) · 2025Article
- Transcriptomic response in planktonic and biofilm-associated cells of Streptococcus mutans treated with sublethal concentrations of chlorhexidine.FEMS microbiology letters · 2025Article
- Synthetic antimicrobial peptide LD4-PP protects the host againstFrontiers in immunology · 2025Article
- Artemisinin May Disrupt Hyphae Formation by Suppressing Biofilm-Related Genes ofAntibiotics (Basel, Switzerland) · 2024Article
- Enhancing Presurgical Infant Orthopedic Appliances: Characterization, Mechanics, and Biofilm Inhibition of a Novel Chlorhexidine-Halloysite Nanotube-Modified PMMA.International journal of biomaterials · 2024Article
- Article
- A graphene microelectrode array based microfluidic device forNanoscale advances · 2023Article
- Identification of potent anti-Candida metabolites produced by the soft coral associated Streptomyces sp. HC14 using chemoinformatics.Scientific reports · 2023Article
- Role of Chlorhexidine and Herbal Oral Rinses in Managing Periodontitis.International dental journal · 2023Article
- Fungal gut microbiota dysbiosis in systemic lupus erythematosus.Frontiers in microbiology · 2023Article
- The antibiofilm activity of selected substances used in oral health prophylaxis.BMC oral health · 2022Article
- A stable cyclized antimicrobial peptide derived from LL-37 with host immunomodulatory effects and activity against uropathogens.Cellular and molecular life sciences : CMLS · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesRecurrent vulvovaginal candidiasis (RVVC) causes significant morbidity. Candida albicans is the main pathogen associated with both sporadic and recurrent candidiasis. Due to unsatisfactory treatment effect, the impact of chlorhexidine digluconate and fluconazole alone or in combination on C. albicans and biofilm was investigated.
methodsVaginal C. albicans isolates from 18 patients with recurrent candidiasis and commensals from 19 asymptomatic women were isolated by culture. Crystal violet, XTT and colony forming unit assay were used to analyze the effect of chlorhexidine digluconate and fluconazole on growth of C. albicans, formation of new and already established, mature, biofilm.
resultsFluconazole reduced the growth of planktonic C. albicans. However, in established biofilm, fluconazole had no effect on the candida cells and was not able to disperse and reduce the biofilm. By contrast, chlorhexidine digluconate had a direct killing effect on C. albicans grown both planktonically and in biofilm. Chlorhexidine digluconate also dispersed mature biofilm and inhibited formation of new biofilm. No major differences were observed between commensal isolates and candida causing recurrent vulvovaginitis with respect to biofilm or growth after chlorhexidine digluconate treatment.
conclusionBiofilm is a problem in patients with recurrent vulvovaginal candidiasis reducing the effect of antifungal treatment. Development of new treatment strategies are urgently needed to decrease the recurrences. In already established biofilm, chlorhexidine digluconate dispersed the biofilm and was more effective in eradicating candida compared to fluconazole. Future treatment strategy may thus be a combination of chlorhexidine digluconate and fluconazole and prophylactic use of chlorhexidine digluconate to prevent biofilm formation and restrict infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.